These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27861538)

  • 1. Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.
    Menten-Dedoyart C; Serrano Navacerrada ME; Bartholome O; Sánchez Gil J; Neirinckx V; Wislet S; Becker G; Plenevaux A; Van den Ackerveken P; Rogister B
    PLoS One; 2016; 11(11):e0166525. PubMed ID: 27861538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
    Ohno Y; Tokudome K
    CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiety-like features and spatial memory problems as a consequence of hippocampal SV2A expression.
    Serrano ME; Bartholomé O; Van den Ackerveken P; Ferrara A; Rogister B; Plenevaux A; Tirelli E
    PLoS One; 2019; 14(6):e0217882. PubMed ID: 31166988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
    Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
    PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling.
    Ohno Y; Ishihara S; Terada R; Kikuta M; Sofue N; Kawai Y; Serikawa T; Sasa M
    Biochem Biophys Res Commun; 2009 Dec; 390(3):415-20. PubMed ID: 19751703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats.
    Wang L; Shi J; Wu G; Zhou F; Hong Z
    Epilepsy Res; 2014 Nov; 108(9):1483-91. PubMed ID: 25205164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
    Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
    Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice.
    Venkatesan K; Alix P; Marquet A; Doupagne M; Niespodziany I; Rogister B; Seutin V
    J Neurosci Res; 2012 Dec; 90(12):2317-27. PubMed ID: 22847229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking.
    Harper CB; Small C; Davenport EC; Low DW; Smillie KJ; Martínez-Mármol R; Meunier FA; Cousin MA
    J Neurosci; 2020 Jun; 40(23):4586-4595. PubMed ID: 32341095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus.
    Ohno Y; Okumura T; Terada R; Ishihara S; Serikawa T; Sasa M
    Neurosci Lett; 2012 Feb; 510(2):93-8. PubMed ID: 22266237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.